Becton Dickinson Launches Innovative Elyra™ Thulium Fiber Laser System for Urologic Care

Becton, Dickinson and Company (BDX) capitalizes on innovation in urologic care with the launch of its new Elyra™ Thulium Fiber Laser (TFL) System. This cutting-edge technology is specifically tailored for managing kidney stones and conducting soft tissue procedures, marking a significant advancement in the company’s medical product portfolio. Designed to enhance procedural efficiency and versatility for urologic teams, the Elyra™ TFL System leverages Thulium Fiber Laser technology, significantly improving stone dusting capabilities and reducing the risk of stone migration during procedures. This innovative approach showcases BD's commitment to elevating the standard of care in urology, while also addressing the intricate challenges faced in current clinical practices.

The Elyra™ TFL System stands out with its air-cooled design that reduces noise, making it an operator-friendly choice in clinical settings. It is available in two configurations—Elyra™ and Elyra™ Plus—allowing healthcare facilities to select the option that best fits their operational needs. Its features include an intuitive user interface, quick-start capabilities, customizable presets, and an optional wireless footswitch to streamline workflows. As stated by Mike Cusack, worldwide president of Urology and Critical Care at BD, this system is a testament to BD's dedication to delivering high-quality, innovative solutions that enhance clinical outcomes for patients.

Following positive feedback from initial clinical cases at a leading medical center, the Elyra™ TFL System is now available in the U.S., further solidifying BD's position in the urologic care market. This strategic expansion complements their comprehensive portfolio of solutions for stone management, which includes access, dilation, visualization, fragmentation, removal, and drainage technologies. As BD continues to innovate and optimize performance in urologic care, the healthcare community can anticipate more robust offerings that prioritize patient safety and procedure efficiency.

In addition to launching the Elyra™ TFL System, BD is navigating leadership changes with the appointment of Peter Menziuso as the Executive Vice President and President of BD Interventional. He is set to assume his role on June 1, 2026, bringing over 30 years of healthcare leadership experience to the company. Moreover, BD has expanded its partnership with Bactiguard to focus on infection prevention, specifically developing coated Foley catheters, indicating the company’s ongoing commitment to enhancing patient care across its diverse product lines.